ESMO 2004 Nausea e Vomito da Chemioterapia: Ottimizzazione del Trattamento

Coates A. , Abraham S. , Kaye S.B. : On the reciving end patients perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol, 19: 203, 1983.

Schnell F.M. : Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist, 8: 187–198, 2003.

Grunberg S.M. , Hesketh P.J. : Control of chemotherapy-induced emesis. N Engl J Med, 329: 1790–1796, 1993.

Gralla RJ, Osoba D, Kris MG et al for the American Society of Clinical Oncology: Recommendations for the use of antiemetics. Evidence-based, clinical practice guidelines. J Clin Oncol, 17: 2971–2994, 1999.

Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol, 9: 811–819, 1998.

DeVane C.L. , Substance P. : A new era, a new role. Pharmacotherapy, 21: 1061–1069, 2001.

Kramer M.S. , Cutler N. , Feighner J. : Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281: 1640–1645, 1998.

Hesketh P.J. : Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer, 9: 350–354, 2001.

Tattersall F.D. , Rycroft W. , Francis B. : Tachykinin NKl receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology, 35: 1121–1129, 1996.

Pisters K.M. , Kris M.G. : Treatment-related nausea and vomiting. In: Principles and practice of supportive oncology, Berger A. , Portenoy R.K. , Weissman J.E. (Eds), pp 165–177, Lippincott-Raven, Philadelphia, PA, 1998.

Kris M.G. , Gralla R.J. , Clark R.A. : Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol, 3: 1379–1384, 1985.

Tavorath R. , Hesketh P.J. : Drug treatment of chemotherapy-induced delayed emesis. Drugs, 52: 639–648, 1996.

Hesketh P.J. , Van Belle S. , Aapro M. : Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer, 39: 1074–1080, 2003.

Cocquyt V. , Van Belle S. , Reinhardt R.R. : Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer, 37: 835–842, 2001.

Campos D. , Pereira J.R. , Reinhardt R.R. : Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol, 19: 1759–1767, 2001.

Merck & Co Inc: EMEND® (aprepitant) capsules: prescribing information. USA (online). Available from URL: http://www.merck.com

Tattersall F.D. , Rycroft W. , Cumberbatch M. : The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology, 39: 652–653, 2000.

Dando T.M. , Perry C.M. : Aprepitant. A review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs, 64: 777–794, 2004.

Van Belle S. , Lichtnitser M.R. , Navari R.M. : Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonist. Cancer, 94: 3032–3041, 2002.

Navari R. , Reinhardt R. , Gralla R.J. : Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med, 340: 190–195, 1999.

De Wit R. , Herrstedt J. , Rapoport B. : The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer, 40: 403–410, 2004.

Chawla S.P. , Grunberg S.M. , Gralla R.J. : Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer, 97: 2290–2300, 2003.

Martin A.R. , Pearson J.D. , Cai B. : Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis. Qual Life Res, 9: 18, 2000.

Gralla R.J. , Warr D.G. , Carides A.D. : Effect of aprepitant on antiemetic protection in patients receiving moderately emetogenic chemotherapy plus high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Proc ASCO, 23: abstr 8137, 2004.

Hesketh P.J. , Grunberg S.M. , Gralla R.J. : The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The aprepitant protocol 052 study group. J Clin Oncol, 21: 4112–4119, 2003.

Poli-Bigelli S. , Rodrigues-Pereira J. , Carides A.D. : Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97: 3090–3098, 2003.